Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Five Under 5: Top Oncology Videos for the Week of 10/5

October 12th 2025

The top 5 OncLive TV videos of the week cover insights in uterine leiomyosarcoma, myelofibrosis, polycythemia vera, breast cancer, and multiple myeloma.

OST-HER2 Displays Potential OS Benefit in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

October 10th 2025

OST-HER2 produced a potential overall survival benefit at 2 years in recurrent, fully resected, pulmonary metastatic osteosarcoma.

Dr Randall on the Benefits and Limitations of MRI in Soft Tissue Sarcoma Surveillance

October 9th 2025

R. Lor Randall, MD, FACS, discusses the current paradigm and future trajectory of imaging modalities for the surveillance of soft tissue sarcoma.

FDA Grants Fast Track Designation to ADCE-D01 for Soft Tissue Sarcoma

October 9th 2025

The FDA granted fast track designation to ADCE-D01 for the treatment of soft tissue sarcoma.

Dr Van Tine on Investigating Olaparib Plus Temozolomide vs Investigator’s Choice of Therapy in Advanced Uterine Leiomyosarcoma

October 6th 2025

Brian A. Van Tine, MD, PhD, discusses the use of olaparib plus temozolomide in advanced uterine leiomyosarcoma following progression on chemotherapy.

OncLive’s September EMA Regulatory Recap: Key EU Approvals in Oncology

October 2nd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in September 2025.

From the Lab to the Clinic: Exploring DFMO’s Potential to Prevent Metastatic Disease in Children With Osteosarcoma and Ewing Sarcoma

October 1st 2025

DFMO shows promise in reducing metastasis in osteosarcoma and Ewing sarcoma, with phase 2 trials underway to test its role as maintenance therapy.

Dr Randall on Challenges Associated With Incorporating Surgical Protocols Into Sarcoma Clinical Trials

September 30th 2025

R. Lor Randall, MD, FACS, discusses the challenges associated with incorporating surgical protocols into clinical trials evaluating sarcoma treatments.

Dr Nadler on the Inherent Complexity of Diagnosing Sarcomas

September 23rd 2025

Eric Nadler, MD, MPP, discusses the inherent complexity of diagnosing sarcomas.

Dr Randall on Advancing Prosthetic Embodiment in Sarcoma Amputation

September 18th 2025

R. Lor Randall, MD, FACS, discusses future research directions for advancing prosthetic embodiment for patients with sarcoma undergoing amputation.

European Commission Green-Lights Vimseltinib for Symptomatic, Unresectable TGCT

September 18th 2025

Vimseltinib earned approval from the European Commission for the treatment of symptomatic, unresectable tenosynovial giant cell tumors.

MRI and Ultrasound May Be Best Used in Tandem for Surveillance Imaging in Soft Tissue Sarcoma

September 12th 2025

Ultrasound is cheaper, faster, and is widely available compared with MRI, but is it enough to displace the gold standard imaging tool?

Recent FDA Approvals and Ongoing Research Expand Treatment Options for Soft Tissue Sarcoma: With Samantha A. Armstrong, MD; and Karine Tawagi, MD

September 8th 2025

Drs Armstrong and Tawagi discuss key aspects of soft tissue sarcoma management.

Five Under 5: Top Oncology Videos for the Week of 8/31

September 7th 2025

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

Dr Van Tine on Olaparib Plus Temozolomide in Advanced Uterine Leiomyosarcoma

September 2nd 2025

Brian A. Van Tine, MD, PhD, discussed trial findings with olaparib plus temozolomide in advanced uterine leiomyosarcoma following prior chemotherapy.

Molecular Research With Benign, Self-Limiting Bone Lesion May Unlock New Treatment Avenues for RAS/MAPK-Activated Tumors

August 29th 2025

R. Lor Randall, MD, FACS, spreads awareness about the benign, self-correcting nature of non-ossifying fibromas, which are commonly confused with sarcoma.

First-Line Anlotinib Plus Chemo Approved in China for Advanced Soft Tissue Sarcoma

August 29th 2025

The combination of anlotinib plus chemotherapy has been approved in China for the treatment of patients with advanced soft tissue sarcoma.

Dr Randall on the Identification and Management of Non-Ossifying Fibromas

August 29th 2025

R. Lor Randall, MD, FACS, discusses the management of non-ossifying fibromas, and how this differs from that of malignant tumors.

Dr D’Amato on the Rationale for Studying Olaparib/Temozolomide in Leiomyosarcoma

August 28th 2025

Gina Z. D’Amato, MD, discusses the rationale for investigating olaparib plus temozolomide in previously treated advanced uterine leiomyosarcoma.

Palbociclib Demonstrates Disease Control in Advanced Chordoma Harboring p16, CDKN2A Loss

August 27th 2025

Palbociclib hit the primary end point of disease control in a phase 2 study of patients with advanced chordoma harboring p16 and/or CDKN2A loss.